Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 20478528 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Kamikubo Y, et al. (2010) Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1. Cancer Cell 17, 455-68 20478528
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S249-p - AML1 (human)
Orthologous residues
AML1 (human): S249‑p, AML1 iso2 (human): S249‑p, AML1 iso8 (human): S276‑p, AML1 (mouse): S249‑p, AML1 (rat): S249‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  293T (epithelial), bone marrow, ME1
 Cellular systems studied:  cell lines, tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
CBFB (human) increase
MYH11 (human) CBFB (human) inhibit treatment-induced increase
MYH11 (human) CBFB (human) no effect upon treatment-induced increase in leukemic cells

S276-p - AML1 iso8 (human)
Orthologous residues
AML1 (human): S249‑p, AML1 iso2 (human): S249‑p, AML1 iso8 (human): S276‑p, AML1 (mouse): S249‑p, AML1 (rat): S249‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  293T (epithelial), bone marrow, ME1
 Cellular systems studied:  cell lines, tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
CBFB (human) increase
MYH11 (human) CBFB (human) inhibit treatment-induced increase
MYH11 (human) CBFB (human) no effect upon treatment-induced increase in leukemic cells

S303-p - AML1 iso8 (human)
Orthologous residues
AML1 (human): S276‑p, AML1 iso2 (human): S276‑p, AML1 iso8 (human): S303‑p, AML1 (mouse): S276‑p, AML1 (rat): S275‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia
 Relevant cell lines - cell types - tissues:  293T (epithelial), bone marrow, ME1
 Cellular systems studied:  cell lines, tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
CBFB (human) increase
MYH11 (human) CBFB (human) inhibit treatment-induced increase
MYH11 (human) CBFB (human) no effect upon treatment-induced increase in leukemic cells

S249-p - AML1 (mouse)
Orthologous residues
AML1 (human): S249‑p, AML1 iso2 (human): S249‑p, AML1 iso8 (human): S276‑p, AML1 (mouse): S249‑p, AML1 (rat): S249‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia
 Relevant cell lines - cell types - tissues:  bone marrow, D43, FL
 Cellular systems studied:  cell lines, tissue
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
MYH11 (mouse) decrease
MYH11 (mouse) increase in leukemic cells

S276-p - AML1 (mouse)
Orthologous residues
AML1 (human): S276‑p, AML1 iso2 (human): S276‑p, AML1 iso8 (human): S303‑p, AML1 (mouse): S276‑p, AML1 (rat): S275‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia
 Relevant cell lines - cell types - tissues:  bone marrow, D43, FL
 Cellular systems studied:  cell lines, tissue
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
MYH11 (mouse) decrease
MYH11 (mouse) increase in leukemic cells


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.